In search for geroprotectors: In silico screening and in vitro validation of signalome-level mimetics of young healthy state

Aging

Volumn 8, Issue 9, 2016, Pages 2127-2152

  Aliper, Alexander ^a   Belikov, Aleksey V ^b   Garazha, Andrew ^a,b,c   Jellen, Leslie ^a,d   Artemov, Artem ^a   Suntsova, Maria ^e   Ivanova, Alena ^e   Venkova, Larisa ^a,g   Borisov, Nicolas ^a,g   Buzdin, Anton ^g   Mamoshina, Polina ^a   Putin, Evgeny ^a   Swick, Andrew G ^h   Moskalev, Alexey ^a,b,f,i,j   Zhavoronkov, Alex ^a,k  

^a Insilico Medicine Inc   (United States)

^b MOSCOW INSTITUTE OF PHYSICS AND TECHNOLOGY   (Russian Federation)

^c Centre for Biogerontology and Regenerative Medicine   (Russian Federation)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e Oncology and Immunology   (Russian Federation)

^f INSTITUTE OF BIOLOGY   (Russian Federation)

^g Pathway Pharmaceuticals   (Hong Kong)

^h Scientific Affairs and Medical Development Life Extension Inc   (United States)

ⁱ GEORGE MASON UNIVERSITY   (United States)

^j ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^k The Biogerontology Research Foundation   (United Kingdom)

more..

Author keywords

Aging; Drug discovery; Drug repurposing; Geroprotector; Screening

Indexed keywords

AGING; ANIMAL; COMPUTER SIMULATION; DRUG EFFECTS; HUMAN; LONGEVITY; PHYSIOLOGY;

AGING; ANIMALS; COMPUTER SIMULATION; HUMANS; LONGEVITY;

EID: 84991461070     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.101047     Document Type: Article

References (85)

1. Arai H, Ouchi Y, Toba K, Endo T, Shimokado K, Tsubota K, Matsuo S, Mori H, Yumura W, Yokode M, Rakugi H, Ohshima S. Japan as the front-runner of super-aged societies: perspectives from medicine and medical care in Japan. Geriatr Gerontol Int. 2015; 15:673-87. doi: 10.1111/ggi.12450
2. Halaweish I, Alam HB. Changing demographics of the American population. Surg Clin North Am. 2015; 95:1-10. doi: 10.1016/j.suc.2014.09.002
3. Spillman BC, Lubitz J. The effect of longevity on spending for acute and long-term care. N Engl J Med. 2000; 342:1409-15. doi: 10.1056/NEJM200005113421906
4. Zhavoronkov A, Litovchenko M. Biomedical progress rates as new parameters for models of economic growth in developed countries. Int J Environ Res Public Health. 2013; 10:5936-52. doi: 10.3390/ijerph10115936
5. Moskalev AA, Aliper AM, Smit-McBride Z, Buzdin A, Zhavoronkov A. Genetics and epigenetics of aging and longevity. Cell Cycle. 2014; 13:1063-77. doi: 10.4161/cc.28433
6. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013; 153:1194-217. doi: 10.1016/j.cell.2013.05.039
7. Partridge L, Thornton J, Bates G. The new science of ageing. Philos Trans R Soc Lond B Biol Sci. 2011; 366:6-8. doi: 10.1098/rstb.2010.0298
8. Zhavoronkov A, Moskalev A. Editorial: Should We Treat Aging as a Disease? Academic, Pharmaceutical, Healthcare Policy, and Pension Fund Perspectives. Front Genet. 2016; 7:17. doi: 10.3389/fgene.2016.00017
9. Zhavoronkov A, Cantor CR. Methods for structuring scientific knowledge from many areas related to aging research. PLoS One. 2011; 6:e22597. doi: 10.1371/journal.pone.0022597
10. Moskalev A, Zhikrivetskaya S, Shaposhnikov M, Dobrovolskaya E, Gurinovich R, Kuryan O, Pashuk A, Jellen LC, Aliper A, Peregudov A, Zhavoronkov A. Aging Chart: a community resource for rapid exploratory pathway analysis of age-related processes. Nucleic Acids Res. 2016; 44:D894-99. doi: 10.1093/nar/gkv1287
11. Weinert BT, Timiras PS. Invited review: theories of aging. J Appl Physiol (1985). 2003; 95:1706-16. doi: 10.1152/japplphysiol.00288.2003
12. Fontana L, Partridge L, Longo VD. Extending healthy life span-from yeast to humans. Science. 2010; 328:321-26. doi: 10.1126/science.1172539
13. Zhavoronkov A, Bhullar B. Classifying aging as a disease in the context of ICD-11. Front Genet. 2015; 6:326. doi: 10.3389/fgene.2015.00326
14. Bulterijs S, Hull RS, Björk VC, Roy AG. It is time to classify biological aging as a disease. Front Genet. 2015; 6:205. doi: 10.3389/fgene.2015.00205
15. Moskalev A, Chernyagina E, de Magalhães JP, Barardo D, Thoppil H, Shaposhnikov M, Budovsky A, Fraifeld VE, Garazha A, Tsvetkov V, Bronovitsky E, Bogomolov V, Scerbacov A, et al. Geroprotectors.org: a new, structured and curated database of current therapeutic interventions in aging and age-related disease. Aging (Albany NY). 2015; 7:616-28. doi: 10.18632/aging.100799.
16. Ehninger D, Neff F, Xie K. Longevity, aging and rapamycin. Cell Mol Life Sci. 2014; 71:4325-46. doi: 10.1007/s00018-014-1677-1
17. Bulterijs S. Metformin as a geroprotector. Rejuvenation Res. 2011; 14:469-82. doi: 10.1089/rej.2011.1153
18. Menendez JA, Cufí S, Oliveras-Ferraros C, Vellon L, Joven J, Vazquez-Martin A. Gerosuppressant metformin: less is more. Aging (Albany NY). 2011; 3:348-62. doi: 10.18632/aging.100316
19. Menendez JA, Joven J. One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin. Aging (Albany NY). 2012; 4:894-98. doi: 10.18632/aging.100523
20. Moskalev A, Chernyagina E, Tsvetkov V, Fedintsev A, Shaposhnikov M, Krut'ko V, Zhavoronkov A, Kennedy BK. Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic. Aging Cell. 2016; 15:407-15. doi: 10.1111/acel.12463
21. Scannell JW, Bosley J. When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis. PLoS One. 2016; 11:e0147215. doi: 10.1371/journal.pone.0147215
22. Bernabe RD, van Thiel GJ, Raaijmakers JA, van Delden JJ. Decision theory and the evaluation of risks and benefits of clinical trials. Drug Discov Today. 2012; 17:1263-69. doi: 10.1016/j.drudis.2012.07.005
23. Rung J, Brazma A. Reuse of public genome-wide gene expression data. Nat Rev Genet. 2013; 14:89-99. doi: 10.1038/nrg3394
24. Corominas-Faja B, Santangelo E, Cuyàs E, Micol V, Joven J, Ariza X, Segura-Carretero A, García J, Menendez JA. Computer-aided discovery of biological activity spectra for anti-aging and anti-cancer olive oil oleuropeins. Aging (Albany NY). 2014; 6:731-41. doi: 10.18632/aging.100691
25. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002; 30:207-10. doi: 10.1093/nar/30.1.207.
26. Barrett T, Edgar R. Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol. 2006; 411:352-69. doi: 10.1016/S0076-6879(06)11019-8
27. Akella LB, DeCaprio D. Cheminformatics approaches to analyze diversity in compound screening libraries. Curr Opin Chem Biol. 2010; 14:325-30. doi: 10.1016/j.cbpa.2010.03.017
28. Zhavoronkov A, Buzdin AA, Garazha AV, Borisov NM, Moskalev AA. Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front Genet. 2014; 5:49. doi: 10.3389/fgene.2014.00049
29. Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY, Borisov NM. Oncofinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Front Genet. 2014; 5:55. doi: 10.3389/fgene.2014.00055
30. Shaposhnikov M, Latkin D, Plyusnina E, Shilova L, Danilov A, Popov S, Zhavoronkov A, Ovodov Y, Moskalev A. The effects of pectins on life span and stress resistance in Drosophila melanogaster. Biogerontology. 2014; 15:113-27. doi: 10.1007/s10522-013-9484-x
31. Cho S, Hwang ES. Fluorescence-based detection and quantification of features of cellular senescence. Methods Cell Biol. 2011; 103:149-88. doi: 10.1016/B978-0-12-385493-3.00007-3
32. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 1995; 92:9363-67. doi: 10.1073/pnas.92.20.9363
33. Borisov NM, Terekhanova NV, Aliper AM, Venkova LS, Smirnov PY, Roumiantsev S, Korzinkin MB, Zhavoronkov AA, Buzdin AA. Signaling pathway activation profiles make better markers of cancer than expression of individual genes. Oncotarget. 2014; 5:10198-205. doi: 10.18632/oncotarget.2548
34. Alexandrova E, Nassa G, Corleone G, Buzdin A, Aliper AM, Terekhanova N, Shepelin D, Zhavoronkov A, Tamm M, Milanesi L, Miglino N, Weisz A, Borger P. Large-scale profiling of signalling pathways reveals an asthma specific signature in bronchial smooth muscle cells. Oncotarget. 2016; 7:25150-61. doi: 10.18632/oncotarget.7209
35. Shepelin D, Korzinkin M, Vanyushina A, Aliper A, Borisov N, Vasilov R, Zhukov N, Sokov D, Prassolov V, Gaifullin N, Zhavoronkov A, Bhullar B, Buzdin A. Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human. Oncotarget. 2016; 7:656-70. doi: 10.18632/oncotarget.6394
36. Aliper AM, Csoka AB, Buzdin A, Jetka T, Roumiantsev S, Moskalev A, Zhavoronkov A. Signaling pathway activation drift during aging: Hutchinson-Gilford Progeria Syndrome fibroblasts are comparable to normal middle-age and old-age cells. Aging (Albany NY). 2015; 7:26-37. doi: 10.18632/aging.100717.
37. Makarev E, Fortney K, Litovchenko M, Braunewell KH, Zhavoronkov A, Atala A. Quantifying signaling pathway activation to monitor the quality of induced pluripotent stem cells. Oncotarget. 2015; 6:23204-12. doi: 10.18632/oncotarget.4673
38. MacRae SL, Croken MM, Calder RB, Aliper A, Milholland B, White RR, Zhavoronkov A, Gladyshev VN, Seluanov A, Gorbunova V, Zhang ZD, Vijg J. DNA repair in species with extreme lifespan differences. Aging (Albany NY). 2015; 7:1171-84. doi: 10.18632/aging.100866.
39. Makarev E, Izumchenko E, Aihara F, Wysocki PT, Zhu Q, Buzdin A, Sidransky D, Zhavoronkov A, Atala A. Common pathway signature in lung and liver fibrosis. Cell Cycle. 2016; 15:1667-73. doi: 10.1080/15384101.2016.1152435
40. Zhavoronkov A, Kanherkar RR, Izumchenko E, Teka M, Cantor C, Manaye K, Sidransky D, West MD, Makarev E, Csoka AB. Pro-fibrotic pathway activation in trabecular meshwork and lamina cribrosa is the main driving force of glaucoma. Cell Cycle. 2016; 15:1643-52. doi: 10.1080/15384101.2016.1170261
41. Yang X, Debonneuil E, Zhavoronkov A, Mishra B. Cancer megafunds with in silico and in vitro validation: accelerating cancer drug discovery via financial engineering without financial crisis. Oncotarget. 2016. 10.18632/oncotarget.9808
42. Mamoshina P, Vieira A, Putin E, Zhavoronkov A. Applications of Deep Learning in Biomedicine. Mol Pharm. 2016; 13:1445-54. doi: 10.1021/acs.molpharmaceut.5b00982
43. Putin E, Mamoshina P, Aliper A, Korzinkin M, Moskalev A, Kolosov A, Ostrovskiy A, Cantor C, Vijg J, Zhavoronkov A. Deep biomarkers of human aging: application of deep neural networks to biomarker development. Aging (Albany NY). 2016; 8:1021-33. doi: 10.18632/aging.100968
44. Artemov A, Aliper A, Korzinkin M, Lezhnina K, Jellen L, Zhukov N, Roumiantsev S, Gaifullin N, Zhavoronkov A, Borisov N, Buzdin A. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation. Oncotarget. 2015; 6:29347-56. doi: 10.18632/oncotarget.5119
45. Buzdin AA, Zhavoronkov AA, Korzinkin MB, Roumiantsev SA, Aliper AM, Venkova LS, Smirnov PY, Borisov NM. The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis. Front Mol Biosci. 2014; 1:8. doi: 10.3389/fmolb.2014.00008
46. Jellen LC, Aliper A, Buzdin A, Zhavoronkov A. Screening and personalizing nootropic drugs and cognitive modulator regimens in silico. Front Syst Neurosci. 2015; 9:4. doi: 10.3389/fnsys.2015.00004
47. Spindler SR, Mote PL, Lublin AL, Flegal JM, Dhahbi JM, Li R. Nordihydroguaiaretic Acid Extends the Lifespan of Drosophila and Mice, Increases Mortality-Related Tumors and Hemorrhagic Diathesis, and Alters Energy Homeostasis in Mice. J Gerontol A Biol Sci Med Sci. 2015; 70:1479-89. doi: 10.1093/gerona/glu190
48. Strong R, Miller RA, Astle CM, Floyd RA, Flurkey K, Hensley KL, Javors MA, Leeuwenburgh C, Nelson JF, Ongini E, Nadon NL, Warner HR, Harrison DE. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell. 2008; 7:641-50. doi: 10.1111/j.1474-9726.2008.00414.x
49. Büchter C, Ackermann D, Havermann S, Honnen S, Chovolou Y, Fritz G, Kampkötter A, Wätjen W. Myricetin-mediated lifespan extension in Caenorhabditis elegans is modulated by DAF-16. Int J Mol Sci. 2013; 14:11895-914. doi: 10.3390/ijms140611895
50. Spindler SR, Li R, Dhahbi JM, Yamakawa A, Sauer F. Novel protein kinase signaling systems regulating lifespan identified by small molecule library screening using Drosophila. PLoS One. 2012; 7:e29782. doi: 10.1371/journal.pone.0029782
51. Ye X, Linton JM, Schork NJ, Buck LB, Petrascheck M. A pharmacological network for lifespan extension in Caenorhabditis elegans. Aging Cell. 2014; 13:206-15. doi: 10.1111/acel.12163
52. Vayndorf EM, Lee SS, Liu RH. Whole apple extracts increase lifespan, healthspan and resistance to stress in Caenorhabditis elegans. J Funct Foods. 2013; 5:1236-43. doi: 10.1016/j.jff.2013.04.006
53. Flurkey K, Astle CM, Harrison DE. Life extension by diet restriction and N-acetyl-L-cysteine in genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2010; 65:1275-84. doi: 10.1093/gerona/glq155
54. Abbas S, Wink M. Epigallocatechin gallate from green tea (Camellia sinensis) increases lifespan and stress resistance in Caenorhabditis elegans. Planta Med. 2009; 75:216-21. doi: 10.1055/s-0028-1088378
55. Niu Y, Na L, Feng R, Gong L, Zhao Y, Li Q, Li Y, Sun C. The phytochemical, EGCG, extends lifespan by reducing liver and kidney function damage and improving age-associated inflammation and oxidative stress in healthy rats. Aging Cell. 2013; 12:1041-49. doi: 10.1111/acel.12133
56. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012; 27:3-9. doi: 10.3892/or.2011.1487
57. Miller RA, Harrison DE, Astle CM, Floyd RA, Flurkey K, Hensley KL, Javors MA, Leeuwenburgh C, Nelson JF, Ongini E, Nadon NL, Warner HR, Strong R. An Aging Interventions Testing Program: study design and interim report. Aging Cell. 2007; 6:565-75. doi: 10.1111/j.1474-9726.2007.00311.x
58. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988; 319:1557-62. doi: 10.1056/NEJM198812153192401
59. Deepmala D, Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 2015; 55:294-321. doi: 10.1016/j.neubiorev.2015.04.015
60. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E, and Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci. 2005; 238:31-39. doi: 10.1016/j.jns.2005.06.003
61. Huentelman MJ, Stephan DA, Talboom J, Corneveaux JJ, Reiman DM, Gerber JD, Barnes CA, Alexander GE, Reiman EM, Bimonte-Nelson HA. Peripheral delivery of a ROCK inhibitor improves learning and working memory. Behav Neurosci. 2009; 123:218-23. doi: 10.1037/a0014260
62. Song Y, Chen X, Wang L-Y, Gao W, Zhu M-J. Rho kinase inhibitor fasudil protects against β-amyloid-induced hippocampal neurodegeneration in rats. CNS Neurosci Ther. 2013; 19:603-10. doi: 10.1111/cns.12116
63. Reiners JJ Jr, Lee JY, Clift RE, Dudley DT, Myrand SP. PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol Pharmacol. 1998; 53:438-45.
64. Halicka HD, Zhao H, Li J, Lee Y-S, Hsieh T-C, Wu JM, Darzynkiewicz Z. Potential anti-aging agents suppress the level of constitutive mTOR-and DNA damage-signaling. Aging (Albany NY). 2012; 4:952-65. doi: 10.18632/aging.100521
65. Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle. 2009; 8:1896-900. doi: 10.4161/cc.8.12.8809.
66. Zhang Y-J, Fang J-Y, Sun D-F, Zhao S-L, Shen G-F, Zheng Q, Zhu HY. [Synergistic effect of rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells]. Zhonghua Zhong Liu Za Zhi. 2007; 29:889-93.
67. Rapoport M, Ferreira A. PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J Neurochem. 2000; 74:125-33. doi: 10.1046/j.1471-4159.2000.0740125.x.
68. Gennaro G, Ménard C, Giasson E, Michaud S-E, Palasis M, Meloche S, Rivard A. Role of p44/p42 MAP kinase in the age-dependent increase in vascular smooth muscle cell proliferation and neointimal formation. Arterioscler Thromb Vasc Biol. 2003; 23:204-10. doi: 10.1161/01.ATV.0000053182.58636.BE.
69. Cánepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF, Ogara MF. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life. 2007; 59:419-26. doi: 10.1080/15216540701488358
70. Sato S, Kawamata Y, Takahashi A, Imai Y, Hanyu A, Okuma A, Takasugi M, Yamakoshi K, Sorimachi H, Kanda H, Ishikawa Y, Sone S, Nishioka Y, et al. Ablation of the p16(INK4a) tumour suppressor reverses ageing phenotypes of klotho mice. Nat Commun. 2015; 6:7035. doi: 10.1038/ncomms8035
71. Kuzuhara T, Suganuma M, Fujiki H. Green tea catechin as a chemical chaperone in cancer prevention. Cancer Lett. 2008; 261:12-20. doi: 10.1016/j.canlet.2007.10.037
72. Wolfram S, Raederstorff D, Preller M, Wang Y, Teixeira SR, Riegger C, Weber P. Epigallocatechin gallate supplementation alleviates diabetes in rodents. J Nutr. 2006; 136:2512-18.
73. Wang Z, Zhang L, Liang Y, Zhang C, Xu Z, Zhang L, Fuji R, Mu W, Li L, Jiang J, Ju Y, Wang Z. Cyclic AMP Mimics the Anti-ageing Effects of Calorie Restriction by Up-Regulating Sirtuin. Sci Rep. 2015; 5:12012. doi: 10.1038/srep12012
74. Origuchi T, Migita K, Nakashima T, Honda S, Yamasaki S, Hida A, Kawakami A, Aoyagi T, Kawabe Y, Eguchi K. Regulation of cyclooxygenase-2 expression in human osteoblastic cells by N-acetylcysteine. J Lab Clin Med. 2000; 136:390-94. doi: 10.1067/mlc.2000.110369
75. Berniakovich I, Laricchia-Robbio L, Izpisua Belmonte JC. N-acetylcysteine protects induced pluripotent stem cells from in vitro stress: impact on differentiation outcome. Int J Dev Biol. 2012; 56:729-35. doi: 10.1387/ijdb.120070ji
76. Leikam C, Hufnagel A, Schartl M, Meierjohann S. Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence. Oncogene. 2008; 27:7070-82. doi: 10.1038/onc.2008.323
77. Fitzgerald AL, Osman AA, Xie T-X, Patel A, Skinner H, Sandulache V, Myers JN. Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells. Cell Death Dis. 2015; 6:e1678. doi: 10.1038/cddis.2015.44
78. Chen G, Shi J, Hu Z, Hang C. Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine. Mediators Inflamm. 2008; 2008:716458. doi:10.1155/2008/716458
79. Semwal DK, Semwal RB, Combrinck S, Viljoen A. Myricetin: A Dietary Molecule with Diverse Biological Activities. Nutrients. 2016; 8:90. doi: 10.3390/nu8020090
80. Singh P, Bast F. Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitro. Invest New Drugs. 2015; 33:575-93. doi: 10.1007/s10637-015-0240-8
81. Kumamoto T, Fujii M, Hou D-X. Myricetin directly targets JAK1 to inhibit cell transformation. Cancer Lett. 2009; 275:17-26. doi: 10.1016/j.canlet.2008.09.027
82. Cammarano MS, Nekrasova T, Noel B, Minden A. Pak4 induces premature senescence via a pathway requiring p16INK4/p19ARF and mitogen-activated protein kinase signaling. Mol Cell Biol. 2005; 25:9532-42. doi: 10.1128/MCB.25.21.9532-9542.2005
83. Kuhn M, Letunic I, Jensen LJ, Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016; 44:D1075-79. doi: 10.1093/nar/gkv1075
84. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999; 20:109-17. doi: 10.2165/00002018-199920020-00002
85. Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. Mol Pharm. 2016; 13:2524-30. doi: 10.1021/acs.molpharmaceut.6b00248